

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 May 2024 (02.05.2024)



(10) International Publication Number
WO 2024/092195 A1

(51) International Patent Classification:

A61K 31/4745 (2006.01) A61K 9/48 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2023/078018

(22) International Filing Date:

27 October 2023 (27.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/420,409	28 October 2022 (28.10.2022)	US
63/427,305	22 November 2022 (22.11.2022)	US
63/453,989	22 March 2023 (22.03.2023)	US
63/525,044	05 July 2023 (05.07.2023)	US

(71) Applicant: **CORCEPT THERAPEUTICS INCORPORATED** [US/US]; 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(72) Inventors: **MANN, Grace**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **TUDOR, Iulia Cristina**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **GUYER, William**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **HUNT, Hazel**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **CUSTODIO, Joseph**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(54) Title: TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT





FIG. 2A

(57) **Abstract:** Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, having the chemical structure illustrated as. Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the

[Continued on next page]

(74) **Agent:** GAO, Chuan et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.